Your browser version may not work well with NCBI's Web applications. More information here...
1: Biochem Biophys Res Commun. 2007 Jul 13;358(4):1096-101. Epub 2007 May 15.
Related Articles, Links
Click here to read Click here to read
The mechanism of action of nitric oxide-donating aspirin.

Kashfi K, Rigas B.

Department of Physiology and Pharmacology, City University of New York Medical School, New York, NY 10031, USA. Kashfi@med.cuny.edu

NO-donating aspirin (NO-ASA) is a promising anticancer drug. We studied the contribution of NO-ASA's components (ASA, NO-releasing moiety, and spacer linking them) to its effect. The ASA and NO-releasing moieties play no biological role: ASA inhibits the growth of colon cancer cells >100-fold less potently that NO-ASA; and denitrated NO-ASA plus the NO-donor SNAP releasing the same amount of NO as NO-ASA, inhibit the growth of cancer cells >50-fold less potently than NO-ASA. The biologically active moiety of NO-ASA is the spacer: it is chemically reactive (studies with NO-ASA radiolabeled at the spacer demonstrated that it binds to proteins); and compounds in which the ASA or the NO-releasing groups are replaced inhibit cell growth similar to NO-ASA. We propose a mechanism of action of NO-ASA involving formation of quinone methide from its para and ortho isomers and of a carbocation from the meta, with the NO-releasing group functioning as a leaving group.

PMID: 17512900 [PubMed - indexed for MEDLINE]